Report post
"Jefferies' top biotech analyst predicts a potential biotech boom in 2024, citing the Bristol Meyers Karuna deal as a precedent. Cramer highlights a biotech stock that could be worth over $100 billion with FDA approval. Agile Therapeutics Inc. (AGRX) is poised for a big jump, offering investors a significant opportunity. Stay tuned for updates and forecasts on AGRX stock."

The World's Leading Crypto Trading Platform

Get my welcome gifts